GTHX - G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium | Benzinga
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from the Company's Phase 2 trial (NCT02978716) will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), held December 5th through 9th in San Antonio, TX. A copy of the poster will be made available on the G1 Therapeutics website following the presentation here.
Results in the poster include:
- Median overall survival (OS) for patients who received subsequent lines of anticancer therapy (SACT) after discontinuation of study treatment was 32.7 months for patients who had previously received trilaciclib prior to gemcitabine/carboplatin (GCb) compared to 12.8 months for patients who had previously received GCb only (no trilaciclib), with increasing separation of survival curves over time.
- Improved survival and sustained separation of curves was also observed in patients unable to receive SACT, although the magnitude of benefit was smaller (median 9.4 months for patients who had previously received trilaciclib vs 5.4 months for patients who had previously received chemotherapy alone).
- Notably, median OS from the start of the first SACT was 14.0 months in patients who had previously received trilaciclib prior to GCb compared to 5.8 months in patients who received GCb only (no trilaciclib).
- For patients who received any SACT after discontinuation of study treatment, demographics and clinical characteristics including, time from end of study treatment to first SACT, and type of SACT ...